See more : Maple Gold Mines Ltd. (MGM.V) Income Statement Analysis – Financial Results
Complete financial analysis of Apogee Therapeutics, Inc. (APGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apogee Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- FreightCar America, Inc. (RAIL) Income Statement Analysis – Financial Results
- Oakajee Corporation Limited (OKJ.AX) Income Statement Analysis – Financial Results
- Powerwrap Limited (PWL.AX) Income Statement Analysis – Financial Results
- EF-ON Inc. (9514.T) Income Statement Analysis – Financial Results
- Maxvision Technology Corp. (002990.SZ) Income Statement Analysis – Financial Results
Apogee Therapeutics, Inc. (APGE)
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 68.42M | 27.79M |
| General & Administrative | 24.58M | 2.94M |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 24.58M | 2.94M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 93.00M | 30.73M |
| Cost & Expenses | 93.00M | 30.73M |
| Interest Income | 9.02M | 92.00K |
| Interest Expense | 0.00 | 9.15M |
| Depreciation & Amortization | 9.02M | 33.52M |
| EBITDA | -83.99M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -93.00M | -30.73M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.02M | -9.06M |
| Income Before Tax | -83.99M | -39.79M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -33.52K |
| Net Income | -83.99M | -39.79M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -3.36 | -0.79 |
| EPS Diluted | -3.36 | -0.79 |
| Weighted Avg Shares Out | 25.01M | 50.67M |
| Weighted Avg Shares Out (Dil) | 25.01M | 50.67M |
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs
Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering
Apogee Therapeutics to raise up to $263.1M in IPO
IPO Update: Apogee Therapeutics Proposes Terms For $250 Million IPO
Apogee Therapeutics sets IPO terms, to be valued at up to $774.5 mln
U.S. IPO Weekly Recap: Nano-Cap Debuts In Short And Quiet Holiday Week
Source: https://incomestatements.info
Category: Stock Reports